nangibotide
Peptideexperimental
Nangibotide is an inhibitor of TREM-1, a receptor found on certain white blood cells. Activation of TREM-1 stimulates inflammation. Nangibotide is therefore being investigated as a treatment for the overwhelming inflammation typically seen in severe sepsis. — Wikipedia
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2016 (NCT03463044)
Timeline
Indications
Mechanism of action
Triggering receptor expressed on myeloid cells 1 inhibitor
Chemistry & pharmacology
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaNangibotide ↗
- ChEMBLCHEMBL4297793 ↗
Also known as
- motrem
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04429334 | Phase 2 | Jun 30, 2020 | Inotrem |
| NCT04055909 | Phase 2 | Nov 30, 2019 | Inotrem |
| NCT03158948 | Phase 2 | Jun 1, 2017 | Inotrem |
| NCT03463044 | Phase 1 | Apr 1, 2016 | Inotrem, Richmond Pharmacology |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Inotrem | For profit | 4 | 4 | 2 | 2016 |
| Richmond Pharmacology | For profit | 1 | 0 | 1 | 2016 |
2 organizations
Page 1 / 1